2012-000793-30: International Study for Treatment of Standard Risk Childhood Relapsed Acute Lymphoblastic Leukemia 2010 |
|
|
| Completed | 3 | 1242 | Europe, RoW | Epratuzumab, IMMU-103, Solution for infusion, ENDOXAN 200 mg ENDOXAN 500 mg ENDOXAN 1 g, CYTOSAR 100 mg CYTOSAR 500 mg CYTOSAR 1 g, Fortecortin, Etoposid, Zavedos, HOLOXAN, Puri-Nethol, METHOTREXAT, Mitoxantron, Oncaspar, Lanvis, Vincristine, Vindesine, Methotrexate, Methotrexat, CYTOSAR | Charité - University Hospital of Berlin, Manchester University NHS Foundation Trust, Turku University Hospital, EU Project FP7, Deutsche Kinderkrebsstiftung, Immunomedics, Deutsche kinderkrebsstiftung, Turku UNiversity Hospital | Acute lymphoblastic leukemia (ALL), Acute lymphoblastic leukemia (ALL), Diseases [C] - Cancer [C04] | | | | |
2004-001563-21: A Phase II, Single-Arm Trial of Naked Epratuzumab, an Anti-CD22 Humanized Antibody, in Patients with Waldenström\'s Macroglobulinemia |
|
|
| Ongoing | 2 | 53 | Europe | epratuzumab, IMMU-103, | Immunomedics, Inc. | Waldenström\'s Macroglobulinemia (WM) is an uncommon B-cell lymphoproliferative disorder that predominantly involves older patients with a slight male preponderance. WM resembles myeloma and chronic lymphocytic leukemia, but has been described as a low-grade lymphoplasmacytic lymphoma characterized by its over production of monoclonal immunoglobulin M (IgM). | | | | |